September 25, 2018

Catabasis Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne

Catabasis Pharmaceuticals, Inc. announced the initiation of PolarisDMD, the Company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy. PolarisDMD clinical trial sites across the United States will open in the coming days for enrollment of the…

Learn More

August 22, 2018

ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne

  ReveraGen BioPharma announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne. This VISION-DMD study will enroll approximately 120…

Learn More

August 2, 2018

Mallinckrodt Announces First Patient Enrolled in Phase 2 Study of MNK-1411 in Duchenne Muscular Dystrophy

  PPMD is excited to learn that Mallinckrodt enrolled the first patient in their Phase 2 study assessing the efficacy and safety of the investigational drug MNK-1411 (cosyntropin, also known as tetracosactide). We look forward…

Learn More

June 26, 2018

Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne

ReveraGen BioPharma, with the Cooperative International Neuromuscular Research Group (CINRG), conducted an international clinical trial of vamorolone at 11 CINRG sites in 6 countries (US, Canada, Australia, Israel, UK, and Sweden). ReveraGen reports that the…

Learn More